Organogenesis is a regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care, surgical, and sports medicine markets. The company's mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients. Organogenesis has a portfolio of products in the advanced wound care, surgical, and sports medicine markets, including PuraPly Antimicrobial, Apligraf and Dermagraft, which are FDA-approved for the treatment of chronic wounds. The company was founded in 1985 and is headquartered in Franklin, Massachusetts.